683 Capital Management’s XBiotech XBIT Stock Holding History

683 Capital Management’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-60,000	Closed	-$628K	–	182
2019 Q3	$628K	Hold	60,000	–	–	0.07%	92
2019 Q2	$455K	Buy	+60,000	New	+$522K	0.04%	115

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CAM

ClariVest Asset Management San Diego, California $980M AUM 60.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

683 Capital Management's XBIT Position: Q4 2019 in Review

683 Capital Management sold out of XBiotech (XBIT) in Q4 2019, closing a stake of 60,000 shares — an estimated $628K sold.

683 Capital Management first reported a position in XBIT in Q2 2019 and held it in 2 quarters. The position peaked at $628K in Q3 2019. 60 funds tracked by Wall St. Rank hold XBIT as of Q4 2019.

683 Capital Management reported no remaining XBiotech position as of Q4 2019 after selling out during the quarter.
683 Capital Management sold 60,000 XBiotech shares in Q4 2019, an estimated $628K.
683 Capital Management first reported a position in XBiotech in Q2 2019 and held it in 2 quarters.
683 Capital Management's XBiotech position peaked at $628K in Q3 2019.
60 funds tracked by Wall St. Rank held XBiotech as of Q4 2019.

Based on 683 Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.